Signaling to the ribosome in cancer - It is more than just mTORC1

IUBMB Life

Volumn 63, Issue 2, 2011, Pages 79-85

  Hannan, Katherine M ^a   Sanij, Elaine ^a,b   Hein, Nadine ^a   Hannan, Ross D ^a,b,c   Pearson, Richard B ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

cancer; PI3K AKT mTORC1; protein synthesis; ribosome

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN;

BIOGENESIS; CANCER GROWTH; CARCINOGENESIS; HUMAN; NONHUMAN; PROTEIN SYNTHESIS REGULATION; REVIEW; RIBOSOME; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; HUMANS; MICE; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; RIBOSOMES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 79952126044     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.428     Document Type: Review

References (65)

1. Jiang, B. H., and, Liu, L. Z., (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv. Cancer Res 102, 19-65.
2. Laplante, M., and, Sabatini, D. M., (2009) mTOR signaling at a glance. J. Cell. Sci. 122 (Pt 20), 3589-3594.
3. Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A, Kuehl, W. M., Gray, N. S., and, Sabatini, D. M., (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873-886.
4. Fayard, E., Xue, G., Parcellier, A., Bozulic, L., and, Hemmings, B. A., (2011) Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr. Top. Microbiol. Immunol. 346, 31-56.
5. Matheny, R. W. Jr., and, Adamo, M. L., (2009) Current perspectives on Akt Akt-ivation and Akt-ions. Exp. Biol. Med. (Maywood) 234, 1264-1270.
6. Altomare, D. A., and, Testa, J. R., (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455-7464. (Pubitemid 41637985)
7. Memmott, R. M., and, Dennis, P. A., (2009) Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 21, 656-664.
8. Vander Haar, E., Lee, S. I., Bandhakavi, S., Griffin, T. J., and. Kim, D. H., (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell. Biol. 9, 316-323. (Pubitemid 46344611)
9. Oshiro, N., Takahashi, R., Yoshino, K., Tanimura, K., Nakashima, A., Eguchi, S., Miyamoto, T., Hara, K., Takehana, K., Avruch, J., Kikkawa, U., and, Yonezawa, K., (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem. 282, 20329-20339. (Pubitemid 47100038)
10. Brandenburger, Y., Jenkins, A., Autelitano, D. J., and, Hannan, R. D., (2001) Increased expression of UBF is a critical determinant for rRNA synthesis and hypertrophic growth of cardiac myocytes. FASEB J. 15, 2051-2053.
11. Hannan, R. D., Jenkins, A., Jenkins, A. K., and, Brandenburger, Y., (2003) Cardiac hypertrophy: a matter of translation. Clin. Exp. Pharmacol. Physiol. 30, 517-527. (Pubitemid 37011588)
12. Ruggero, D., and, Pandolfi, P. P., (2003) Does the ribosome translate cancer? Nat. Rev. Cancer 3, 179-192. (Pubitemid 37328870)
13. Choo, A. Y., and, Blenis, J., (2009) Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8, 567-572.
14. Ma, X. M., and, Blenis, J., (2009) Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell. Biol. 10, 307-318.
15. Mayer, C., and, Grummt, I., (2006) Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 25, 6384-6391. (Pubitemid 44582283)
16. Jastrzebski, K., Hannan, K. M., Tchoubrieva, E. B., Hannan, R. D., and. Pearson, R. B., (2007) Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 25, 209-226.
17. Jefferies, H. B., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and, Thomas, G., (1997) Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16, 3693-3704. (Pubitemid 27250062)
18. Meyuhas, O., (2000) Synthesis of the translational apparatus is regulated at the translational level. Eur. J. Biochem. 267, 6321-6330.
19. Ruvinsky, I., and, Meyuhas, O., (2006) Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci. 31, 342-348. (Pubitemid 43903237)
20. Shima, H., Pende, M., Chen, Y., Fumagalli, S., Thomas, G., and, Kozma, S. C., (1998) Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17, 6649-6659. (Pubitemid 28521798)
21. 2+ signaling, prolyl hydroxylases, and mTOR. J. Cell. Physiol. 217, 674-685.
22. Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivieres, S., Mercep, L., and, Ferrari, S., (1998) Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem. 273, 14424-14429. (Pubitemid 28319162)
23. Law, B. K., Waltner-Law, M. E., Entingh, A. J., Chytil, A., Aakre, M. E., Norgaard, P., and, Moses, H. L., (2000) Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J. Biol. Chem. 275, 38261-38267. (Pubitemid 32009146)
24. Shahbazian, D., Roux, P. P., Mieulet, V., Cohen, M. S., Raught, B., Taunton, J., Hershey, J. W., Blenis, J., Pende, M., and, Sonenberg, N., (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 25, 2781-2791. (Pubitemid 43980385)
25. Carayol, N., Katsoulidis, E., Sassano, A., Altman, J. K., Druker, B. J., and, Platanias, L. C., (2008) Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J. Biol. Chem. 283, 8601-8610.
26. Wang, L., Wang, X., and, Proud, C. G., (2000) Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Am. J. Physiol. Heart Circ. Physiol. 278, H1056-H1068. (Pubitemid 30235480)
27. Ma, X. M., Yoon, S. O., Richardson, C. J., Julich, K., and, Blenis, J., (2008) SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 133, 303-313. (Pubitemid 351508301)
28. Hannan, K. M., Brandenburger, Y., Jenkins, A., Sharkey, K., Cavanaugh, A., Rothblum, L., Moss, T., Poortinga, G., Mcarthur, G. A., Pearson, R. B., and, Hannan, R. D., (2003) mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 23, 8862-8877. (Pubitemid 37433385)
29. Wang, X., and, Proud, C. G., (2006) The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 21, 362-369. (Pubitemid 44511764)
30. White, R. J., and, Sharrocks, A. D., (2010) Coordinated control of the gene expression machinery. Trends Genet. 26, 214-220.
31. Kantidakis, T., Ramsbottom, B. A., Birch, J. L., Dowding, S. N., and, White, R. J., (2010) mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc. Natl. Acad. Sci. USA 107, 11823-11828.
32. Moss, T., Langlois, F., Gagnon-Kugler, T., and, Stefanovsky, V., (2007) A housekeeper with power of attorney: the rRNA genes in ribosome biogenesis. Cell. Mol. Life Sci. 64, 29-49. (Pubitemid 46159444)
33. Stefanovsky, V. Y., and, Moss, T., (2008) The splice variants of UBF differentially regulate RNA polymerase I transcription elongation in response to ERK phosphorylation. Nucleic Acids Res. 36, 5093-6101.
34. Dai, M. S., and, Lu, H., (2008) Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J. Cell. Biochem. 105, 670-677.
35. Bader, A. G., and, Vogt, P. K., (2004) An essential role for protein synthesis in oncogenic cellular transformation. Oncogene 23, 3145-3150. (Pubitemid 38638826)
36. Brognard, J., and, Hunter, T., (2011) Protein kinase signaling networks in cancer. Curr. Opin. Genet. Dev., 21, 4-11.
37. Poortinga, G., Wall, M., Sanij, E., Siwicki, K., Ellul, J., Brown, D., Holloway, T., Hannan, R., Mcarthur, G., c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Res., Accessed 28 Dec 2010, [Epub ahead of print].
38. Poortinga, G., Hannan, K. M., Snelling, H., Walkley, C. R., Jenkins, A., Sharkey, K., Wall, M., Brandenburger, Y., Palatsides, M., Pearson, R. B., Mcarthur, G. A., and, Hannan, R. D., (2004) MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J. 23, 3325-3335. (Pubitemid 39209156)
39. Bodem, J., Dobreva, G., Hoffmann-Rohrer, U., Iben, S., Zentgraf, H., Delius, H., Vingron, M., and, Grummt, I., (2000) TIF-IA, the factor mediating growth-dependent control of ribosomal RNA synthesis, is the mammalian homolog of yeast Rrn3p. EMBO Rep. 1, 171-175.
40. Sanij, E., and, Hannan, R. D., (2009) The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin. Epigenetics 4, 374-382.
41. Sanij, E., Poortinga, G., Sharkey, K., Hung, S., Holloway, T. P., Quin, J., Robb, E., Wong, L. H., Thomas, W. G., Stefanovsky, V., Moss, T., Rothblum, L., Hannan, K. M., Mcarthur, G. A., Pearson, R. B., and, Hannan, R. D., (2008) UBF levels determine the number of active ribosomal RNA genes in mammals. J. Cell. Biol. 183, 1259-1274.
42. Zhao, J., Yuan, X., Frodin, M., and, Grummt, I., (2003) ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol. Cell. 11, 405-413. (Pubitemid 36293834)
43. Wall, M., Poortinga, G., Hannan, K. M., Pearson, R. B., Hannan, R. D., and, Mcarthur, G. A., (2008) Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood 112, 2305-2317.
44. White, R. J., (2008) RNA polymerases I and III, non-coding RNAs and cancer. Trends Genet. 24, 622-629.
45. Van Riggelen, J., Yetil, A., and, Felsher, D. W., (2010) MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 10, 301-309.
46. Wendel, H. G., De Stanchina, E., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., and, Lowe, S. W., (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337. (Pubitemid 38418805)
47. Uddin, S., Hussain, A. R., Siraj, A. K., Manogaran, P. S., Al-Jomah, N. A., Moorji, A., Atizado, V., Al-Dayel, F., Belgaumi, A., El-Solh, H., Ezzat, A., Bavi, P., and, Al-Kuraya, K. S., (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108, 4178-4186. (Pubitemid 44913290)
48. Ruggero, D., (2009) The role of Myc-induced protein synthesis in cancer. Cancer Res. 69, 8839-8843.
49. Kim, E. K., and, Choi, E. J., (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 1802, 369-405.
50. Campbell, I. G., Russell, S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S., Cristiano, B. E., Pearson, R. B., and, Phillips, W. A., (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681. (Pubitemid 39446895)
51. Campbell, I. G., Russell, S. E., and, Phillips, W. A., (2005) PIK3CA mutations in ovarian cancer. Clin. Cancer Res. 11 (19 Pt 1), 7042; author reply 7042- 7043.
52. Dempke, W. C., and, Heinemann, V., (2010) Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Anticancer Res. 30, 4673-4677.
53. Hruban, R. H., Goggins, M., Parsons, J., and, Kern, S. E., (2000) Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969-2972. (Pubitemid 30637716)
54. Engelman, J. A., (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562.
55. Albert, S., Serova, M., Dreyer, C., Sablin, M. P., Faivre, S., and, Raymond, E., (2010) New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Exp. Opin. Investig. Drugs 19, 919-930.
56. Ghobrial, I. M., Roccaro, A., Hong, F., Weller, E., Rubin, N., Leduc, R., Rourke, M., Chuma, S., Sacco, A., Jia, X., Azab, F., Azab, A. K., Rodig, S., Warren, D., Harris, B., Varticovski, L., Sportelli, P., Leleu, X., Anderson, K. C., and, Richardson, P. G., (2010) Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin. Cancer Res. 16, 1033-1041.
57. Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., and, Bardelli, A., (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 101, 1308-1324.
58. Drygin, D., Siddiqui-Jain, A., O'brien, S., Schwaebe, M., Lin, A., Bliesath, J., Ho, C. B., Proffitt, C., Trent, K., Whitten, J. P., Lim, J. K., Von Hoff, D., Anderes, K., and, Rice, W. G., (2009) Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 69, 7653-7661.
59. Drygin, D., Rice, W. G., and, Grummt, I., (2010) The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu. Rev. Pharmacol. Toxicol. 50, 131-156.
60. Drygin, D., Lin, A., Bliesath, J., Ho, C., O'brien, S., Proffitt, C., Omori, M., Haddach, M., Schwaebe, M., Siddiqui-Jain, A., Streiner, N., Quin, J. Sanij, E., Bywater, M., Hannan, R., Ryckman, D., Anderes, K., and, Rice, W., Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res., Accessed 1 Feb 2011, [Epub ahead of print].
61. Grandori, C., Gomez-Roman, N., Felton-Edkins, Z. A., Ngouenet, C., Galloway, D. A., Eisenman, R. N., and, White, R. J., (2005) c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat. Cell. Biol., 311-318. (Pubitemid 40331133)
62. Narla, A., and, Ebert, B. L., (2010) Ribosomopathies: human disorders of ribosome dysfunction. Blood 115, 3196-3205.
63. Song, M. J., Yoo, E. H., Lee, K. O., Kim, G. N., Kim, H. J., Kim, S. Y., and, Kim, S. H., (2010) A novel initiation codon mutation in the ribosomal protein S17 gene (RPS17) in a patient with Diamond-Blackfan anemia. Pediatr. Blood Cancer 54, 629-631.
64. Ebert, B. L., Pretz, J., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E., Ellis, S. R., and, Golub, T. R., (2008) Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451, 335-339.
65. Luft, F., (2010) The rise of a ribosomopathy and increased cancer risk. J. Mol. Med. 88, 1-3.